ANI Pharmaceuticals FY Conference Summary Company Overview - ANI Pharmaceuticals is a profitable high-growth biopharmaceutical organization focusing on rare diseases, projecting over $1 billion in sales for 2026 with significant growth expected [2][22] - The company reported a 44% year-over-year growth in 2025, with a projected growth of 23% for 2026 [2][22] Core Business Segments Rare Disease Business - The rare disease segment is expected to represent about 60% of total company revenues in 2026, with projected sales of $618 million to $658 million, reflecting a 51% growth from 2025 [2][9] - Cortrophin Gel, the lead asset, is anticipated to grow 55% to 65%, reaching $540 million to $575 million in 2026 [8][22] - The rare disease business has shown an 84% growth in 2025, driven by key specialties including neurology, rheumatology, nephrology, and pulmonology [4][9] Generics Business - The Generics segment achieved a 28% year-over-year growth in 2025, supported by strong R&D capabilities and operational execution [5][18] - The company plans to maintain a cadence of 10 to 15 new product launches annually and invests a high single-digit percentage of Generics revenue into R&D [6][19] Strategic Priorities for 2026 1. **Accelerate Transformation into Rare Disease Company**: Focus on maximizing growth opportunities for Cortrophin Gel and expanding into under-penetrated specialty indications [5][12] 2. **Continue Execution on Generics Business**: Leverage operational excellence and R&D capabilities to enhance cash generation [6][19] 3. **Disciplined Capital Allocation**: Explore opportunities for inorganic growth in the rare disease sector while investing in Generics R&D [6][21] Market Dynamics - The ACTH market, which includes Cortrophin, is projected to approach $1 billion in sales by 2025, with a 45% year-over-year growth [10] - The company has identified significant unmet needs in various indications, with a focus on severe acute gouty arthritis flares, representing an addressable population of approximately 285,000 patients [11][12] Financial Performance - ANI Pharmaceuticals reported $883 million in revenues for 2025, with adjusted non-GAAP EBITDA of $230 million, reflecting a 47% year-over-year growth [4][22] - The company enters 2026 with over $286 million in cash and a net leverage of 1.5 times debt, indicating strong financial health [21][22] Conclusion - ANI Pharmaceuticals is well-positioned for long-term growth, leveraging cash flows from its Generics business to fuel investments in its rare disease segment, aiming to transform into a leading rare disease company [20][22]

Financial Data and Key Metrics Changes - ANI Pharmaceuticals reported record fourth quarter and full year 2024 results, raising 2025 guidance for total revenues and adjusted non-GAAP EBITDA [10][11] - 2025 revenue is now expected to be between $756 million and $776 million, representing growth of 23% to 26% over 2024 [10][62] - Adjusted non-GAAP EBITDA for 2025 is projected to be between $190 million and $200 million, reflecting growth of 22% to 28% over 2024 [10][62] Business Line Data and Key Metrics Changes - Rare Disease was the primary growth driver in 2024, with Cortrophin Gel generating close to $200 million in sales [11][12] - Generics business achieved 12% revenue growth, marking the third consecutive year of double-digit growth [12] - Fourth quarter revenues for Rare Disease and Brands were $106.9 million, up 97% year-over-year, with Rare Disease revenues more than doubling to $87 million [53][55] Market Data and Key Metrics Changes - The overall ACTH market is expected to have grown about 25% to approximately $660 million in 2024 [38] - There are currently fewer than 5,000 patients on therapy for ILUVIEN and YUTIQ, with an estimated addressable patient population 6 to 10 times higher [89][113] - The demand for Cortrophin Gel increased across all targeted specialties, including neurology, rheumatology, nephrology, pulmonology, and ophthalmology [15][35] Company Strategy and Development Direction - The company aims to broaden its presence in the rare disease space, as evidenced by the acquisition of Alimera Sciences [12][11] - A core strategic rationale for the Alimera acquisition was to add synergistic assets and leverage existing infrastructure to unlock the potential of ILUVIEN and YUTIQ [17][51] - The company plans to continue investing in R&D and commercial initiatives to drive growth in its Rare Disease business [45][51] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for Cortrophin Gel and the overall ACTH market, despite current access issues for ILUVIEN and YUTIQ [89][114] - The company anticipates a typical Q4 to Q1 revenue drop for Cortrophin Gel, followed by strong sequential growth in subsequent quarters [63][90] - Management highlighted the importance of addressing unmet needs in autoimmune disorders and the potential for significant market expansion [39][40] Other Important Information - The company has expanded its U.S. ophthalmology sales team from 30 to 46 representatives to promote ILUVIEN, YUTIQ, and Cortrophin Gel [20][48] - A prefilled syringe for Cortrophin Gel is under FDA review, expected to launch in the second quarter of 2025 [44][45] - The company has taken steps to enhance supply security for ILUVIEN and YUTIQ through partnerships and capacity expansions [22][100] Q&A Session Summary Question: Business development and M&A capacity - Management indicated a thoughtful approach to leverage ratios, historically keeping it under three, and expressed intent to pursue additional business development while maintaining balance sheet health [76][78] Question: Gout's contribution to Cortrophin sales - Currently, 15% of Cortrophin's volume comes from gout, which is seen as a gateway indication for new prescribers [80] Question: Access issues for Alimera assets - Management acknowledged access issues for ILUVIEN and YUTIQ due to funding shortfalls in patient assistance programs but remains confident in long-term growth prospects [88][89] Question: Seasonality impact on Cortrophin - Typical Q4 to Q1 dynamics are expected, with a drop in sales followed by sequential growth, supported by strong early trends [90] Question: Transitioning supply from EyePoint to Siegfried - Management confirmed that supply transitions are being managed carefully, with inventory buildup and a focus on maintaining supply security [100][101]